A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator
Top Cited Papers
Open Access
- 1 February 2018
- journal article
- review article
- Published by Elsevier BV in JACC: Heart Failure
- Vol. 6 (2), 96-104
- https://doi.org/10.1016/j.jchf.2017.08.013
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection FractionJournal of the American Heart Association, 2013
- Riociguat for the Treatment of Chronic Thromboembolic Pulmonary HypertensionThe New England Journal of Medicine, 2013
- Riociguat for the Treatment of Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2013
- A Novel Paradigm for Heart Failure With Preserved Ejection FractionJournal of the American College of Cardiology, 2013
- Endothelial DysfunctionJournal of the American College of Cardiology, 2012
- Low Myocardial Protein Kinase G Activity in Heart Failure With Preserved Ejection FractionCirculation, 2012
- Soluble guanylate cyclase: a potential therapeutic target for heart failureHeart Failure Reviews, 2012
- Effect of Nesiritide in Patients with Acute Decompensated Heart FailureThe New England Journal of Medicine, 2011
- Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary DiseaseCirculation, 2011
- Gender-specific hypertension and responsiveness to nitric oxide in sGCα1 knockout miceCardiovascular Research, 2008